Verrica Pharmaceuticals Total Assets Growth & History (VRCA)
Verrica Pharmaceuticals's total assets was $47.1M for fiscal 2025.
View full Verrica Pharmaceuticals company overviewVerrica Pharmaceuticals annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $47.1M | −$7.0M | −12.94% |
| 2024 | 2024-12-31 | $54.1M | −$27.5M | −33.66% |
| 2023 | 2023-12-31 | $81.6M | $36.9M | +82.46% |
| 2022 | 2022-12-31 | $44.7M | −$35.4M | −44.19% |
| 2021 | 2021-12-31 | $80.1M | $6.0M | +8.05% |
| 2020 | 2020-12-31 | $74.2M | $5.7M | +8.37% |
| 2019 | 2019-12-31 | $68.4M | −$23.5M | −25.55% |
| 2018 | 2018-12-31 | $91.9M | $82.8M | +911.85% |
| 2017 | 2017-12-31 | $9.1M | — | — |
Verrica Pharmaceuticals quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $36.0M | −$3.1M | −7.90% |
| Q1 2026 | 2026-03-31 | $38.8M | −$3.4M | −8.04% |
| Q4 2025 | 2025-12-31 | $47.1M | −$7.0M | −12.94% |
| Q3 2025 | 2025-09-30 | $40.9M | $8.0M | +24.20% |
| Q2 2025 | 2025-06-30 | $39.1M | −$12.9M | −24.81% |
| Q1 2025 | 2025-03-31 | $42.2M | −$24.1M | −36.39% |
| Q4 2024 | 2024-12-31 | $54.1M | −$27.5M | −33.66% |
| Q3 2024 | 2024-09-30 | $32.9M | −$64.2M | −66.11% |
| Q2 2024 | 2024-06-30 | $52.0M | −$10.2M | −16.38% |
| Q1 2024 | 2024-03-31 | $66.3M | −$2.3M | −3.40% |
| Q4 2023 | 2023-12-31 | $81.6M | $36.9M | +82.46% |
| Q3 2023 | 2023-09-30 | $97.1M | $48.0M | +97.67% |
| Q2 2023 | 2023-06-30 | $62.2M | −$1.2M | −1.95% |
| Q1 2023 | 2023-03-31 | $68.6M | −$3.0M | −4.16% |
| Q4 2022 | 2022-12-31 | $44.7M | −$35.4M | −44.19% |
| Q3 2022 | 2022-09-30 | $49.1M | −$39.6M | −44.63% |
| Q2 2022 | 2022-06-30 | $63.4M | −$35.6M | −35.94% |
| Q1 2022 | 2022-03-31 | $71.6M | −$36.5M | −33.75% |
| Q4 2021 | 2021-12-31 | $80.1M | $6.0M | +8.05% |
| Q3 2021 | 2021-09-30 | $88.8M | $8.8M | +11.03% |
| Q2 2021 | 2021-06-30 | $99.0M | $11.8M | +13.52% |
| Q1 2021 | 2021-03-31 | $108.1M | $13.7M | +14.46% |
| Q4 2020 | 2020-12-31 | $74.2M | $5.7M | +8.37% |
| Q3 2020 | 2020-09-30 | $79.9M | $3.9M | +5.08% |
| Q2 2020 | 2020-06-30 | $87.2M | $6.0M | +7.37% |
| Q1 2020 | 2020-03-31 | $94.4M | $8.5M | +9.84% |
| Q4 2019 | 2019-12-31 | $68.4M | −$23.5M | −25.55% |
| Q3 2019 | 2019-09-30 | $76.1M | −$22.7M | −23.01% |
| Q2 2019 | 2019-06-30 | $81.3M | −$23.5M | −22.41% |
| Q1 2019 | 2019-03-31 | $86.0M | — | — |
| Q4 2018 | 2018-12-31 | $91.9M | $82.8M | +911.85% |
| Q3 2018 | 2018-09-30 | $98.8M | — | — |
| Q2 2018 | 2018-06-30 | $104.7M | — | — |
| Q4 2017 | 2017-12-31 | $9.1M | — | — |
Verrica Pharmaceuticals total assets trends
Over the last five fiscal years, Verrica Pharmaceuticals's total assets decreased from $74.2M to $47.1M, a change of −$27.0M. The latest reported quarter, Q2 2026, shows $36.0M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Verrica Pharmaceuticals source filings ↗